Apixaban versus Warfarin in Patients with Atrial Fibrillation

By S. Goto. 2012

4,473 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation (2017, background): “This recommendation is based on the following: (1) recurrences of AF are common both early and late following AF ablation; (2) asymptomatic AF is common, and is more common following AF ablation than prior to AF ablation; (3) AF ablation destroys a portion of the atria and the impact of this on stro”
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. (2018, methodology): “For these drugs, efficacy and safety compared to warfarin was consistent in the (few) underweight patients when compared with the remainder of the study cohort.(30,31) As such, both drugs may be a preferred choice for patients <60 kg.”
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. (2014, positive): “Apixaban is not recommended in patients with severe hepatic impairment.”
Dabigatran versus warfarin in patients with mechanical heart valves. (2013, neutral): “300 mg twice daily 11/45 (24) 79 2/6 (33) 83 13/51 (25) 79”